Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02767089 · ClinicalTrials.gov registry record · Phase 1

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

A Phase 1 study of Healthy Adults, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
37
Enrollment target
1
Study location

NCT02767089: Completed Phase 1 study of Healthy Adults, sponsored by Pfizer.

NCT02767089 is a Phase 1 study of Healthy Adults that has completed, run by Pfizer. The registered enrollment target is 37 participants, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02767089, a Phase 1 study of Healthy Adults, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to further access the utility of biochemical and clinical biomarkers for glucocorticoid-mediated anti-inflammatory effects and safety endpoints against which dissociated agonists of the glucocorticoid receptor (DAGR) will be evaluated in adult healthy volunteers.

Primary Outcome

The change in serum osteocalcin from baseline after treatment on Day 1 and Day 8 will be assessed in each treatment period

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Prednisone

Study Locations (1)

Michigan

  • Jasper Clinic, Inc. - Kalamazoo

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2005-10
Est. Completion 2006-03
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT02767089 record still lists

NCT02767089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (56% lower).

The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02767089 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT02767089 about?

NCT02767089 is a clinical study titled "The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers". The purpose of this study is to further access the utility of biochemical and clinical biomarkers for glucocorticoid-mediated anti-inflammatory effects and safety endpoints against which dissociated agonists of the glucocorticoid receptor (DAGR) will be evaluated in adult healthy volunteers.

What is the current status of trial NCT02767089?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2005-10. Estimated completion is 2006-03.

What conditions does trial NCT02767089 study?

This clinical trial studies the following conditions: Healthy Adults.

What interventions are being tested in trial NCT02767089?

The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG).

Who is sponsoring clinical trial NCT02767089?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02767089 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adults

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02767089's enrollment target sits among peer trials

37 17th of 33 higher than 17 of 33 other Healthy Adults trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Adults trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02767089, the US trial registry maintained by the National Library of Medicine. NCT02767089 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.